Clinical Trials Logo

Clinical Trial Summary

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02771379
Study type Observational
Source Santhera Pharmaceuticals
Contact
Status Completed
Phase
Start date September 2016
Completion date April 16, 2021

See also
  Status Clinical Trial Phase
Completed NCT02796274 - Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Completed NCT02774005 - Study to Assess the Efficacy and Safety of Raxone in LHON Patients Phase 4
Recruiting NCT04912843 - Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy Phase 2/Phase 3
Terminated NCT01389817 - Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) Phase 1/Phase 2
Completed NCT05555784 - Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection